|
[1] TANG LSY, COVERT E, WILSON E, et al. Chronic hepatitis B infection:A review[J]. JAMA, 2018, 319 (17) :1802-1813.
|
|
[2] TERRAULT NA, BZOWEJ NH, CHANG KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63 (1) :261-283.
|
|
[3] TIAN Q, JIA J. Hepatitis B virus genotypes:Epidemiological and clinical relevance in Asia[J]. Hepatol Int, 2016, 10 (6) :854-860.
|
|
[4] SUNBUL M. Hepatitis B virus genotypes:Global distribution and clinical importance[J]. World J Gastroenterol, 2014, 20 (18) :5427-5434.
|
|
[5] BAYLISS J, YUEN L, ROSENBERG G, et al. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBe Ag-positive chronic hepatitis B[J]. Gut, 2017, 66 (11) :2013-2023.
|
|
[6] SUN YH, LEI XY, SAI YP, et al. Relationship between genotypes and clinical manifestation, pathology, and cccDNA in Chinese children with hepatitis B virus-associated glomerulonephritis[J]. World J Pediatr, 2016, 12 (3) :347-352.
|
|
[7] LI X, QIN Y, LIU Y, et al. Pre S deletion profiles of hepatitis B virus (HBV) are associated with clinical presentations of chronic HBV infection[J]. J Clin Virol, 2016, 82:27-32.
|
|
[8] YANG HC, KAO JH. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes:Molecular mechanisms and clinical significance[J]. Emerg Microbes Infect, 2014, 3 (9) :e64.
|
|
[9] CHOTIYAPUTTA W, LOK AS. Hepatitis B virus variants[J].Nat Rev Gastroenterol Hepatol, 2009, 6 (8) :453-462.
|
|
[10] LINDH M, HORAL P, DHILLON AP, et al. Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage[J]. Hepatology, 1996, 24 (3) :494-501.
|
|
[11] CHACHSGF, GOMES-GOUVEA MS, MALTA FM, et al.Basal core promoter and precore mutations among hepatitis B virus circulating in Brazil and its association with severe forms of hepatic diseases[J]. Mem Inst Oswaldo Cruz, 2017, 112 (9) :626-631.
|
|
[11] CHU CM, LIN CC, CHEN YC, et al. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection[J]. Br J Cancer, 2012, 107 (12) :2010-2015.
|
|
[12] TONG S, KIM KH, CHANTE C, et al. Hepatitis B virus e antigen variants[J]. Int J Med Sci, 2005, 2 (1) :2-7.
|
|
[13] LAPALUS M, LAOUENAN C, CARDOSO AC, et al. Precore/Core promoter variants to predict significant fibrosis in both HBe Ag positive and negative chronic hepatitis B[J]. Liver Int, 2015, 35 (9) :2082-2089.
|
|
[14] TSENG TC, LIU CJ, YANG HC, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers[J]. Gut, 2015, 64 (2) :292-302.
|
|
[15] DUCANCELLE A, PIVERT A, BERTRAIS S, et al. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity[J]. J Gastroenterol Hepatol, 2016, 31 (10) :1750-1756.
|
|
[16] KITAB B, ESSAID EL FEYDI A, AFIFI R, et al. Variability in the precore and core promoter regions of HBV strains in Morocco:Characterization and impact on liver disease progression[J].PLo S One, 2012, 7 (8) :e42891.
|
|
[17] CASTELAIN S, DESCAMPS V, BROCHOT E, et al. High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBe Ag-negative chronically infected patients[J]. Arch Virol, 2017, 162 (7) :1913-1920.
|
|
[18] TENG YC, NEO JC, WU JC, et al. Expression of a hepatitis B virus pre-S2 deletion mutant in the liver results in hepatomegaly and hepatocellular carcinoma in mice[J]. J Pathol, 2017, 241 (4) :463-474.
|
|
[19] DONG Q, CHAN HL, LIU Z, et al. A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities[J]. Biochem Biophys Res Commun, 2008, 374 (4) :773-776.
|
|
[20] GONG J, TU W, HAN J, et al. Hepatic SATB1 induces paracrine activation of hepatic stellate cells and is upregulated by HBx[J]. Sci Rep, 2016, 6:37717.
|
|
[21] KANG HJ, CHUNG DH, SUNG CO, et al. SHP2 is induced by the HBx-NF-kappaB pathway and contributes to fibrosis during human early hepatocellular carcinoma development[J]. Oncotarget, 2017, 8 (16) :27263-27276.
|
|
[22] REDELSPERGER F, LEKBABY B, MANDOURI Y, et al. Production of hepatitis B defective particles is dependent on liver status[J]. Virology, 2012, 431 (1-2) :21-28.
|
|
[23] DURIEZ M, MANDOURI Y, LEKBABY B, et al. Alternative splicing of hepatitis B virus:A novel virus/host interaction altering liver immunity[J]. J Hepatol, 2017, 67 (4) :687-699.
|
|
[24] PERRI S, GANEM D. A host factor that binds near the termini of hepatitis B virus pregenomic RNA[J]. J Virol, 1996, 70 (10) :6803-6809.
|
|
[25] WANG J, YU Y, LI G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients[J]. J Hepatol, 2017.[Epub ahead of print]
|
|
[26] KIMURA T, ROKUHARA A, SAKAMOTO Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load[J]. J Clin Microbiol, 2002, 40 (2) :439-445.
|
|
[27] KIMURA T, OHNO N, TERADA N, et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain[J]. J Biol Chem, 2005, 280 (23) :21713-21719.
|
|
[28] SETO WK, TANAKA Y, WONG DK, et al. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels:Re-evaluation of HBsAg seroclearance[J]. Liver Int, 2016, 36 (5) :642-650.
|
|
[29] TADA T, KUMADA T, TOYODA H, et al. Hepatitis B virus corerelated antigen levels predict progression to liver cirrhosis in hepatitis B carriers[J]. J Gastroenterol Hepatol, 2017, 33 (4) :918-925.
|
|
[30] SUN C, CHANG XJ, LI XD, et al. Value of hepatitis B virus core-related antigen in predicting the natural course of chronic hepatitis B and liver fibrosis regression[J]. J Clin Hepatol, 2019, 35 (2) :328-333. (in Chinese) 孙超, 常秀娟, 李晓东, 等. HBcrAg在慢性乙型肝炎自然进程及预判肝纤维化逆转中的应用价值[J].临床肝胆病杂志, 2019, 35 (2) :328-333.
|
|
[31] WANG S, CHEN Z, HU C, et al. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation[J]. J Immunol, 2013, 190 (10) :5142-5151.
|
|
[32] SEEGER C, MASON WS. Hepatitis B virus biology[J]. Microbiol Mol Biol Rev, 2000, 64 (1) :51-68.
|
|
[33] LARSSON SB, MALMSTRM S, HANNOUN C, et al. Mechanisms downstream of reverse transcription reduce serum levels of HBV DNA but not of HBsAg in chronic hepatitis B virus infection[J]. Virol J, 2015, 12:213.
|
|
[34] MASON WS, GILL U S, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J]. Gastroenterology, 2016, 151 (5) :986-998.
|
|
[35] GOYAL SK, JAIN AK, DIXIT VK, et al. HBsAg level as predictor of liver fibrosis in HBe Ag positive patients with chronic hepatitis B virus infection[J]. J Clin Exp Hepatol, 2015, 5 (3) :213-220.
|
|
[36] MARTINOT-PEIGNOUX M, LAPALUS M, ASSELAH T, et al.HBsAg quantification:Useful for monitoring natural history and treatment outcome[J]. Liver Int, 2014, 34 (Suppl 1) :97-107.
|
DownLoad: